Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 5 Issue 5

A Systematic Review on the Analytical Techniques for the Quantification of Valacyclovir

Chodimella Sahitya Bharathi and Mukthinuthalapati Mathrusri Annapurna*

GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India

*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.

Received: April 07, 2021; Published: April 30, 2021

Abstract

  Valacyclovir is used for the treatment of viral infections caused by Herpes simplex viruses which include shingles, chickenpox and genital herpes. Valacyclovir converts rapidly into acyclovir after its oral administration and there by inhibits the viral DNA replication. In the present paper the authors have reviewed the analytical methods already published till now in the literature for the estimation of Valacyclovir in pharmaceutical formulations and in biological samples.

Keywords: Valacyclovir; Drug; DNA

Introduction

  Lines 16-22: Valacyclovir is an anti-viral drug. Valacyclovir is chemically defined as 2-amino-3-methyl butanoate derivative of acyclovir [1,2]. Valacyclovir (Figure 1) has a molecular formula C13H20N6O4 and molecular weight 360.8 g/mole and it is soluble in water. The pKa values of Valacyclovir are found to be 1.90, 9.43 and 7.47 respectively. Valacyclovir is converted into Acyclovir tri phosphate which competitively inhibits viral DNA synthesis by incorporating into the DNA polymerase of virus and finally inactivates and terminates the DNA polymerase chain [3,4].

Figure 1: Chemical structure of valacyclovir.

  Valacyclovir is available as tablets with brand names VALTOVAL (Sun Pharmaceutical Industries Ltd., India) and VALCIVIR (Cipla Ltd, India) etc. with a labelled claim of 500 mg for each of the brand product. Valacyclovir is also available as tablets in combination with Cefotaxime, Ritonavir etc. in marketed formulations. This article summarises the analytical techniques proposed by different authors for the quantification of Valacyclovir. Such analytical techniques include spectrophotometry [5-9] (Table 1), liquid-mass spectrometry [LC-MS] [10], LC-MS/MS [11,12], ultraperformance liquid chromatography [UPLC] [13], high performance liquid chromatography [HPLC] [14-19]. Reverse phase high performance liquid chromatography [RP-HPLC] methods have been used to determine the drug following enantiometric separation [20], in biological fluids [21,22], impurity profiling using Box-Behnken design [23] and related substances [24-26]. Table 2 presents some of the significant chromatographic conditions and parameters.

Reagent

Linearity

(µg/ml)

λmax

(nm)

Comment

Reference

0.1N HCl

5-25

255

UV region

[5]

Vanillin

PDAB

20-100

100-500

428

388

Visible region

UV region

[6]

Distilled water

4-24

 

252

 

UV region

[7]

Phenyl hydrazine HCl/Fe3+/H+

Fe3+/1,10-phenanthroline

2 - 10

5 - 25

520

Visible region

[8]

Sodium acetate (pH 4.0)

Phosphate buffer (pH 5.0)

Phosphate buffer (pH 7.0)

Borate buffer (pH 9.0)

0.1N NaOH

 

1 - 80

251

251

252

253

265

UV region

[9]

Table 1: Review of spectrophotometric methods.

Mobile phase (v/v)

Column

Linearity (µg/ml)

Comment

Ref

Liquid chromatography- Mass spectrometry methods

Acetonitrile: 0.05% Aq. diethyl amine (50:50)

 

Porous graphitized carbon (PGC)

0.02 - 0.80

LC-ESI/MS

Ganciclovir (Internal standard)

Human plasma

[10]

Mobile phase A: 2 mM Ammonium acetate: 0.2% Formic acid:

Mobile phase B: Acetonitrile: 0.2% Formic acid

Waters Atlantis T3 C18

-

LC-MS/MS

(Gradient mode)

Mouse & human plasma

[11]

0.1% Formic acid: Methanol (30:70)

 

Gemini C18

-

LC-ESI-MS/MS

Human plasma and its metabolite (Isocratic mode)

[12]

Ultra performance Liquid chromatography

0.1% o-phosphoric acid: Acetonitrile (70: 30)

-

12.5 - 75

UPLC

[13]

High performance Liquid chromatography

Mobile phase A:

Acetic acid: Water (1∶1000)

Mobile phase B: Methanol (70∶ 30)

ODS C18

 

-

HPLC

[14]

0.1% Formic acid: Acetonitrile (90: 10)

C18 (Develosil)

 

10 - 50

 

 

HPLC

 

[15]

Acetonitrile: Phosphate buffer

(pH- 3.6) (50:50)

Hypersil ODS C18

0.5 - 200

 

HPLC

 

[16]

Acetonitrile: Phosphate buffer

(pH- 3.6) (50:50)

Hypersil, ODS C18

0.5 - 200

 

HPLC

 

[17]

Mobile phase A: NaH2PO4 buffer (pH 3.5 adjusted with dilute ortho phosphoric acid)

Mobile phase B: Acetonitrile: Methanol (60:40)

Hypersil BDS C18

 

 

15 - 225

 

 

HPLC

 

[18]

Acetonitrile: Phosphate buffer

(pH- 3.6) (50:50)

Hypersil ODS C-18

 

0.5 - 200

 

 

HPLC

 

[19]

n-Hexane: Ethanol: Diethyl amine (30:70:0.1)

Chiralpak AD

0.9 - 6

Enantio selective

[20]

Acetonitrile: 0.025 M mono ammonium phosphate buffer (pH 4.0; adjusted with 10% diluted phosphoric acid) (2:98)

1-methylguanosine (Internal standard)

Symmetry Shield RP-8

0.5 - 20

Biological fluids

(Serum Dialysis liquid & Urine)

Run time 12 min

[21]

Acetonitrile: Methanol: 0.067 M KH2PO4 (27:20:53)

Waters Spherisorb C18

0.005 - 20

 

Human serum

[22]

Mobile phase A: Buffer (pH 3): Acetonitrile (95: 5)

Mobile phase B: Acetonitrile: Methanol (90:10) Diluent: Buffer: Acetonitrile (50: 50)

ODS 3V

50 - 150

Box-Behnken design

Impurity Profiling and

Related Products

Run time 40 min

(Gradient mode)

[23]

0.1% aqueous Phosphoric acid (85%): Methanol (90:10)

Daicel Chiral Phase Crown pack CR (+)

0.3 - 6

 

Related substances

[24]

0.015 M Acetic acid: Methanol (95: 5)

ODS

6 - 90

Related substances

[25]

Mobile phase A: Phosphate buffer (KH2PO4): Methanol (90:10)

Mobile phase B: Buffer: Methanol: Acetonitrile (50: 30:20) (pH 6.7 adjusted with Tri ethyl amine)

Inertsil ZODS 3V

 

-

Related substances

Run time 65 min

(Gradient mode)

[26]

Table 2: Review of liquid chromatographic methods.

Conclusion

  The present review has presented some of the analytical techniques employed in the determination of Valacyclovir in various sample matrices. Of all the techniques, high performance liquid chromatographic techniques seem to be the techniques of interest.

References

  1. Budawari S. “The Merck index”. 13th Edition, Merck and Co. Inc., U.S.A. (2001).
  2. Williams DA and Lemke TL. “Foye’s Principles of Medicinal Chemistry”. 5th Edition, Lippincott Williams and Wikins, Wolters Wuwer Health Pvt. Ltd., New Delhi (2006).
  3. HP Range., et al. “Pharmacology”. 5th Edition, Churchill Livingstone (2003).
  4. “Basic and Clinical Pharmacology”. 9th Edition, Mc raw Hill (2004).
  5. Ganesh M., et al. “UV Spectrophotometric method for the estimation of Valacyclovir HCl in tablet dosage form”. E-Journal of Chemistry 3 (2009): 814-818.
  6. Prasad Reddy DV., et al. “Spectrophotometric determination of Valacyclovir hydrochloride in bulk and pharmaceutical formulations”. Asian Journal of Chemistry 4 (2007): 2797-2800.
  7. Sugumaran M and Jothieswari D. “Development and validation of spectroscopic method for estimation of Valacyclovir in tablet dosage form”. Oriental Journal of Chemistry1(2010): 163-165.
  8. Siva Ramakrishna V., et al. “Development and determination of Valacyclovir HCl in pharmaceutical dosage forms by visible spectrophotometry”. International Journal of Pharm Tech Research 3 (2012): 1009-1014.
  9. Reddy Narendra., et al. “Development and validation of new analytical methods for the estimation of Valacyclovir hydrochloride in pharmaceutical dosage form”. Scholars Research Library Der Pharmacia Lettre 1(2016): 296-303.
  10. Maria Kasiari., et al. “Selective and rapid liquid chromatography/negative-ion electrospray ionization mass spectrometry method for the quantification of Valacyclovir and its metabolite in human plasma”. Journal of Chromatography B1-2 (2008): 78-86.
  11. Shi J., et al. “A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of valacyclovir and its metabolite acyclovir in mouse and human plasma”. Journal of Chromatography B 1092 (2018): 447-452.
  12. Yadav M., et al. “Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method”. Journal of Chromatography B 8-9 (2009): 680-688.
  13. Sunkara Namratha and Vijayalakshmi A. “Analytical method development and validation of Valacyclovirin dosage forms by UPLC technique”. Journal of Global Trends in Pharmaceutical Sciences 2 (2020): 7590-7594.
  14. Palacios ML., et al. “Validation of an HPLC Method for the determination of Valacyclovir in pharmaceutical dosage”. Journal of Liquid Chromatography and Related Technologies5 (2005): 751-762.
  15. Rasool SK., et al. “RP-HPLC method for the estimation of Valacyclovir in bulk and pharmaceutical formulations”. International Journal of Pharmacy and Pharmaceutical Sciences 1 (2012): 214-218.
  16. Srinivasa Rao K and Sunil. “Stability-indicating liquid chromatographic method for Valacyclovir”. International Journal of ChemTech Research3 (2009): 702-708.
  17. Dillip Kumar Sahoo and Prafulla Kumar Sahu. “Stability-indicating RP-HPLC method for the determination of Valaciclovir hydrochloride in bulk and pharmaceutical dosage forms”. Chemical Science Transactions 2 (2014): 510-517.
  18. Jahnavi Bandla and Ashok Gorja. “Method development and validation of Valacyclovir hydrochloride assay by RP-HPLC in pharmaceutical dosage form”. International Journal of Advanced Research in Pharmaceutical and Bio Sciences 1 (2013): 33-41.
  19. Juluri Krishna Dutta Tejaswi. “Stability indicating determination of Valacyclovir by RP-HPLC method”. International Journal of Advance Research and Innovative Ideas in Education 3 (2020): 526-532.
  20. Jadhav AS., et al. “Development and validation of enantioselective high performance liquid chromatographic method for Valacyclovir, an antiviral drug in drug substance”. Journal of Pharmaceutical and Biomedical Analysis 4 (2007): 1568-1572.
  21. Pham-Huy C., et al. “Rapid determination of Valacyclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution”. Journal of Chromatography B 1 (1999): 47-53.
  22. Ayhan Savaşer., et al. “Development and validation of an RP‐HPLC method for the determination of Valacyclovir in tablets and human serum and its application to drug dissolution studies”. Journal of Liquid Chromatography and Related Technologies 26 (2003): 1755-1767.
  23. Katakam P., et al. “An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC”. Scientia Pharmaceutica3 (2014): 617-619.
  24. Girija BB., et al. “Development and validation of RP-HPLC method for the determination of Valacyclovir hydrochloride and its related substances in tablet formulation”. International Journal of Pharmaceutical Sciences Review and Research 1 (2014): 53-58.
  25. Mani Ganesh., et al. “Development and validation of RP-HPLC method for the determination of Valacyclovir hydrochloride and its related substances in tablet formulation”. Asian Journal of Chemistry 3 (2011): 1317-1320.
  26. Tholkappiyan B., et al. “Analysis of related substances by high performance liquid chromatography [HPLC] method for Valacyclovir hydrochloride”. The Bioscan 1 (2010): 117-121.

Citation

Citation: Chodimella Sahitya Bharathi and Mukthinuthalapati Mathrusri Annapurna. “A Systematic Review on the Analytical Techniques for the Quantification of Valacyclovir". Acta Scientific Pharmaceutical Sciences 5.5 (2021): 51-55.

Copyright

Copyright: © 2021 Chodimella Sahitya Bharathi and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is November 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US